RE:RE:RE:RE:TheranosticsWhat need to be understood, is that the trailblazing job in that field has been done in Europe in the last 20 years. The pioneering job has been long and careful, but now this field is well known and tools are easy to adapt to new peptides. Thera would not do this job alone, they need to partner with knowlegable scientists in the field. As I wrote before here, there is knowhow in the province of Quebec that Thera could easily partner with. Sherbrooke Unviversity is the main one concerning imaging and Gallium 68 use, while Sacre-Coeur Hospital in Quebec city are the leading experts in the province with Lu177-Dotatate. It would be very easy for Thera to partner with them on a research project on animal. Thera just need to provide them the peptide TH19P01 coupled with the DOTA linker, and xenograft mice with sortilin expressing tumors, and these guys will put the isotopes on the peptide, inject the mice and do a PETscan. Easy to have a proof of concept on animal. If you get that, than do the proper preclinical work, submit an IND, and than go to humans with a careful phase I protocol. That's it. It would be longer for Lu177 because it is very toxic, but for the imaging with Ga68, it should be quicker, since toxicity is much less of an issue.
Lee430 wrote: I asked Leah if she would forward the article to Marsolais, I don't have the chops to do any more than that, hopefully JFM1330 has presented a compelling argument to them for at least looking into this.
jfm1330 wrote: I should add that the prostate cancer version (Lu177-PSMA) is following the same path as the neuroendocrine cancer one (Lu177-Dotatate or Lutathera). It was first available in Europe, and that for many years, before it was finally approved in the US and Canada. So Lu177-PSMA should follow the same path. Novartis is behind it. That being said, the imaging version with Gallium 68 is already approved in the US. Again, Thera needs to get on this track. We can see that the imaging version can get approval faster since Ga68 is only emitting positron, and no real radiations. So safety is much less an issue, and it is a very sensitve tool for tumor detection and measurement.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
https://pubmed.ncbi.nlm.nih.gov/33293081/
https://www.novartis.com/news/media-releases/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-men-metastatic-castration-resistant-prostate-cancer
jfm1330 wrote: This is exactly what I am talking about relentlessly here, but for prostate cancer. Personnally, I was talking about neuroendocrine cancers, which was the cancer for which the first PDCs developped with radioisotopes. In this case it's a more recent development in prostate cancer. It uses a tripeptide linked to a non peptidic part. This peptide based molecule has affinity for the PSMA receptor overexpressed in prostate cancer. The rest is the same. They use the DOTA linker to chelate the isotopes. They now have the imaging version with Gallium 68, the therapeutic version with Lutetium 177, and they already do trials with Actinium 225. Wake up Marsolais and Thera!!!!
https://www.researchgate.net/figure/Chemical-structures-of-DOTAGA-FFKSub-KuE-a-first-generation-tracer-upper-and-PSMA_fig3_278788852
Lee430 wrote: Molecular-targeted liquid radiation, is this simular to what jfm1330 has been refering to that Thera could use with the peptide or a completly different new therapy?
https://www.dailybulletin.com/2021/07/24/new-hope-in-the-fight-against-prostate-cancer-we-can-win-this-war/